# US 10,369,160 B2 · Methods of treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,369,160 B2
- Document ID: US10369160B2
- Status: Granted
- Kind: B2
- Application number: 15/484,379
- Filed: 2017-04-11
- Published: 2017-10-19
- Granted: 2019-08-06
- Earliest claimed: 2016-04-13
- Assignees: Intercept Pharmaceuticals, Inc.
- Applicants: Intercept Pharmaceuticals, Inc.
- Inventors: Antonio Moschetta; Jesus Maria Banales Asurmedi; Luis Bujanda Fernández de Pierola; María Jesús Perugorria Montiel; Oihane Erice Azparren
- Web page: https://patentgrep.com/patent/US10369160B2

## CPC

- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 31/133: having hydroxy groups, e.g. sphingosine
- A61K 47/54: the modifying agent being an organic compound
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods of treating or preventing cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of the invention.

## Claims

### Claim 1

A method of treating or preventing hepatocellular carcinoma in a subject in need thereof comprising administering a therapeutically effective amount of Compound 1:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the hepatocellular carcinoma is selected from the group consisting of early stage hepatocellular carcinoma, non-metastatic hepatocellular carcinoma, primary hepatocellular carcinoma, advanced hepatocellular carcinoma, locally advanced hepatocellular carcinoma, metastatic hepatocellular carcinoma, hepatocellular carcinoma in remission, or recurrent hepatocellular carcinoma.

### Claim 3 (depends on 1)

The method of claim 1, wherein the FXR agonist is the sodium salt of Compound 1.

### Claim 4 (depends on 1)

The method of claim 1, wherein the FXR agonist is the N,N-diethylethaneamine salt of Compound 1.

### Claim 5

A method of treating or preventing hepatocellular carcinoma in a subject in need thereof comprising administering a pharmaceutical composition comprising a therapeutically effective amount of FXR agonist selected from Compound 1:
or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

### Claim 6

A kit for treating or preventing hepatocellular carcinoma in a subject in need thereof comprising Compound 1:
or a pharmaceutically acceptable salt thereof.